Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnostics

References

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Bassi A, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single center retrospective study. Gut 53(10), 1471–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91, 854–862 (2001).
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 347(6), 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Kirsner J, Spencer J. Familial occurrences of ulcerative colitis, regional enteritis and ileocolitis. Ann. Intern. Med. 59, 133–144 (1963).
   PubMed Web of Science ®Google Scholar
• Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124(7), 1767–1773 (2003).
   PubMed Web of Science ®Google Scholar
• Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn’s disease patients. J. Clin. Gastroenterol. 8, 655–657 (1986).
   PubMedGoogle Scholar
• Laharie D, Debeugny S, Peeters M et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 120, 816–819 (2001).
   PubMed Web of Science ®Google Scholar
• Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 38(5), 738–741 (1996).
   PubMed Web of Science ®Google Scholar
• Newman B, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. Curr. Opin. Gastroenterol. 21(4), 401–407 (2005).
   Google Scholar
• Satsangi J, Parkes M, Louis E et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genet. 14(2), 199–202 (1996).
   Google Scholar
• Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379(6568), 821–823 (1996).
   PubMed Web of Science ®Google Scholar
• Parkes M, Barmada MM, Satsangi J, Weeks DE, Jewell DP, Duerr RH. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. Am. J. Hum. Genet. 67(6), 1605–1610 (2000).
   PubMed Web of Science ®Google Scholar
• Brant SR, Panhuysen CI, Bailey-Wilson JE et al. Linkage heterogeneity for the IBD1 locus in Crohn’s disease pedigrees by disease onset and severity. Gastroenterology 119(6), 1483–1490 (2000).
   PubMedGoogle Scholar
• Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411(6837), 599–603 (2001).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411(6837), 603–606 (2001).
   PubMed Web of Science ®Google Scholar
• Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 357(9272), 1925–1928 (2001).
   PubMed Web of Science ®Google Scholar
• Lesage S, Zouali H, Cezard JP et al. CARD15/NOD2 Mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70, 845–857 (2002).
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a meta-analysis. Am. J. Gastroenterol. 99(12), 2393–2404 (2004).
   PubMed Web of Science ®Google Scholar
• Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122, 867–874 (2002).
   PubMed Web of Science ®Google Scholar
• Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology 122, 854–866 (2002).
   PubMed Web of Science ®Google Scholar
• Newman B, Silverberg MS, Gu X et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn’s disease. Am. J. Gastroenterol. 99(2), 306–315 (2004).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Wild G, Kocher K et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am. J. Hum. Genet. 71, 74–83 (2002).
   PubMedGoogle Scholar
• Cavanaugh JA, Adams KE, Quak EJ et al. CARD15/NOD2 risk alleles in the development of Crohn’s disease in the Australian population. Ann. Hum. Genet. 67(1), 35–41 (2003).
   PubMedGoogle Scholar
• Arnott ID, Nimmo ER, Drummond HE et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn’s disease patients: evidence for genetic heterogeneity within Europe? Genet. Immun. 5(5), 417–425 (2004).
   PubMed Web of Science ®Google Scholar
• Bonen DK, Nicolae DL, Moran A et al. Racial differences in NOD2 variation:characterization of NOD2 in African–Americans with Crohn’s disease. Gastroenterology 122, A29–A35 (2002).
   Google Scholar
• Inoue N, Tamura K, Kinouchi Y et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology 123(1), 86–91 (2002).
   PubMed Web of Science ®Google Scholar
• Leong RW, Armuzzi A, Ahmad T et al. NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. Aliment. Pharmacol.Ther. 17(12), 1465–1470 (2003).
   PubMed Web of Science ®Google Scholar
• Colombel J. The CARD15 gene in Crohn’s disease: Are there implications for current clinical practice? Clin. Gastroenterol. Hepatol.. 5–9 (2003).
   PubMedGoogle Scholar
• Yang H, McElree C, Roth MP et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 34, 517–524 (1993).
   PubMed Web of Science ®Google Scholar
• Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am. J. Epidemiol. 149(10), 916–924 (1999).
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 100(2), 350–358 (1991).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Wild G, Kocher K et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am. J. Hum. Genet. 71(1), 74–83 (2002).
   PubMed Web of Science ®Google Scholar
• Idestrom M, Rubio C, Granath F, Finkel Y, Hugot JP. CARD15 mutations are rare in Swedish pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 40(4), 456–460 (2005).
   PubMed Web of Science ®Google Scholar
• Sugimura K, Taylor KD, Lin YC et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn’s disease in Ashkenazi Jews. Am. J. Hum. Genet. 72, 509–519 (2003).
   PubMed Web of Science ®Google Scholar
• Tukel T, Shalata A, Present D et al. Crohn’s disease: frequency and nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental Jewish families. Am. J. Hum. Genet. 74, 623–636 (2004).
   PubMedGoogle Scholar
• Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn’s disease. Gastroenterology 122, 2091–2092 (2002).
   PubMed Web of Science ®Google Scholar
• Buning C, Genschel J, Buhner S et al. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol.Ther. 19(10), 1073–1078 (2004).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 276(7), 4812–4818 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenstiel P, Fantini M, Brautigam K et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 124(4), 1001–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124(4), 993–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Lala S, Ogura Y, Osborne C et al. Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterology 125(1), 47–57 (2003).
   PubMed Web of Science ®Google Scholar
• Dangl JL, Jones JD. Plant pathogens and integrated defence responses to infection. Nature 411(6839), 826–833 (2001).
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. Microbiol. 5(1), 76–80 (2002).
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85(2), 85–95 (2003).
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J. Biol. Chem. 278(8), 5509–5512 (2003).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278(11), 8869–8872 (2003).
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Musch MW, Chang JE et al. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 127(5), 1401–1409 (2004).
   PubMed Web of Science ®Google Scholar
• Inohara N, Koseki T, Lin J et al. An induced proximity model for NF-ΚB activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 275(36), 27823–27831 (2000).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Inohara N, Hernandez LD et al. RICK/Rip2/CARDIAK mediates signaling for receptors of the innate and adaptive immune systems. Nature 416(6877), 194–199 (2002).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 42(4), 477–484 (1998).
   PubMed Web of Science ®Google Scholar
• Bonen DK, Ogura Y, Nicolae DL et al. Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124(1), 140–146 (2003).
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5(9), 581–592 (2003).
   PubMed Web of Science ®Google Scholar
• van Heel DA, Ghosh S, Butler M et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 365(9473), 1794–1796 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307(5710), 731–734 (2005).
   PubMed Web of Science ®Google Scholar
• Lala S, Ogura Y, Osborne C et al. Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterology 125(1), 47–57 (2003).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Lala S, Xin W et al. Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis. Gut 52 (11), 1591–1597 (2003).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut 53(11), 1658–1664 (2004).
   PubMed Web of Science ®Google Scholar
• Rioux JD, Silverberg MS, Daly MJ et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet. 66, 1863–1870 (2000).
   Google Scholar
• Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn’s disease. Nature Genet. 29, 223–228 (2001).
   PubMed Web of Science ®Google Scholar
• Giallourakis C, Stoll M, Miller K et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am. J. Hum. Genet. 73, 205–211 (2003).
   PubMed Web of Science ®Google Scholar
• Mirza MM, Fisher SA, King K et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn’s disease. Am. J. Hum. Genet. 72, 1018–1022 (2003).
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Takazoe M, Tanaka T et al. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn’s disease. J. Hum. Genet. 49(12), 664–668 (2004).
   PubMedGoogle Scholar
• Torok HP, Glas J, Tonenchi L et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn’s disease. Gut 54(10), 1421–1427 (2005).
   PubMed Web of Science ®Google Scholar
• Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn’s disease. Nature Genet. 36(5), 471–475 (2004).
   PubMed Web of Science ®Google Scholar
• Yabuuchi H, Tamai I, Nezu J et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289(2), 768–773 (1999).
   Google Scholar
• Newman B, Gu X, Wintle R et al. A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease. Gastroenterology 128(2), 260–269 (2005).
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Ahmad T, Ling KL et al. Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31. Gut 52(8), 1133–1139 (2003).
   PubMed Web of Science ®Google Scholar
• Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nature Genet. 36(5), 476–480 (2004).
   PubMed Web of Science ®Google Scholar
• Daly MJ, Pearce AV, Farwell L et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur. J. Hum. Genet. 13(7), 835–839 (2005).
   Google Scholar
• Noble CL, Nimmo ER, Drummond H, Smith L, Arnott ID, Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut (2005) Apr 20 [Epub ahead of print].
   Google Scholar
• Hampe J, Schreiber S, Shaw SH et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am. J. Hum. Genet. 64(3), 808–816 (1999).
   PubMed Web of Science ®Google Scholar
• Shah G, Brugada R, Gonzalez O et al. The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics 3(1), 6 (2002).
   Google Scholar
• Wakabayashi M, Ito T, Mitsushima M et al. Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J. Biol. Chem. 278(24), 21709–21714 (2003).
   PubMedGoogle Scholar
• Hollander D. Crohn’s disease – a permeability disorder of the tight junction? Gut 29(12), 1621–1624 (1988).
   PubMedGoogle Scholar
• Peeters M, Geypens B, Claus D et al. Clustering of increased small intestinal permeability in families with Crohn’s disease. Gastroenterology 113(3), 802–807 (1997).
   PubMed Web of Science ®Google Scholar
• Buhner S, Buning C, Genschel J et al. Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut 2005 [Epub ahead of print]
   Google Scholar
• Van Heel DA, Fisher SA, Kirby A et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum. Mol. Genet. 13(7), 763–770 (2004).
   PubMed Web of Science ®Google Scholar
• Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract. Res. Clin. Gastroenterol. 18(3), 577–596 (2004).
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Mirea L, Bull SB et al. A population – and family – based study of Canadian families reveals association of HLA DRB10103 with colonic involvement in inflammatory bowel disease. Inflamm. Bowel Dis. 9(1), 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88(6), 1818–1825 (1985).
   PubMed Web of Science ®Google Scholar
• Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn’s disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 88(6), 1826–1833 (1985).
   PubMedGoogle Scholar
• Griffiths AM, Wesson DE, Shandling B, Corey M, Sherman PM. Factors influencing postoperative recurrence of Crohn’s disease in childhood. Gut 32(5), 491–495 (1991).
   PubMedGoogle Scholar
• Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel Dis. 6(1), 8–15 (2000).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47(4), 487–496 (2000).
   PubMed Web of Science ®Google Scholar
• Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, antiSaccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn’s disease. Inflamm. Bowel Dis. 10(5), 521–528 (2004).
   PubMed Web of Science ®Google Scholar
• Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 126(2), 414–424 (2004).
   PubMed Web of Science ®Google Scholar
• Gasche C, Grundtner P. Genotypes and phenotypes in Crohn’s disease: do they help in clinical management? Gut. 54(1), 162–167 (2005).
   PubMed Web of Science ®Google Scholar
• Brant SR, McGovern DP. NOD2, not yet: con. Inflamm. Bowel Dis. 11(5), 507–509 (2005).
   PubMedGoogle Scholar
• Rubin DT. To test or ‘NOD-2’ test: what are the questions? The balanced viewpoint. Inflamm. Bowel Dis. 11(5), 510–512 (2005).
   PubMedGoogle Scholar
• Satsangi J, Campbell H, Dunlop MG, Porteous MEM. Molecular genetics in gastroenterology: from research success to clinical application. Nature Clin. Prac. Gastroenterol. Hepatol. 2(3), 118–119 (2005).
   PubMedGoogle Scholar
• Silver J. The importance of penetration. Inflamm. Bowel Dis. 9(5), 341 (2003).
   PubMedGoogle Scholar
• van der Linde K, Boor PP, Houwing-Duistermaat JJ, Kuipers EJ, Wilson JH, de Rooij FW. CARD15 and Crohn’s disease: Healthy homozygous carriers of the 3020insC frameshift mutation. Am. J. Gastroenterol. 98, 613–617 (2003).
   PubMedGoogle Scholar
• Esters N, Pierik M, van Steen K et al. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am. J. Gastroenterol. 99(2), 299–305 (2004).
   Google Scholar
• Konda V, Huo D, Hermes G et al. Do inflammatory bowel disease patients want genetic testing? Gastroenterology 125, A369 (2003).
   Google Scholar
• Appleton JL, Mascarenhas J, Esplen MJ et al. Demand for genetic testing for inflammatory bowel disease. Gastroenterology 126, A352 (2004).
   Google Scholar
• McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics 3(1), 89–98 (2002).
   PubMed Web of Science ®Google Scholar
• Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of antiTNF therapy in patients with Crohn’s disease. Pharmacogenomics 5(5), 479–486 (2004).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Rutgeerts P et al. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology 123(1), 106–111 (2002).
   PubMed Web of Science ®Google Scholar
• Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 12(7), 509–515 (2002).
   PubMedGoogle Scholar
• Urcelay E, Mendoza JL, Martinez A et al. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J. Gastroenterol. 11(8), 1187–1192 (2005).
   PubMed Web of Science ®Google Scholar
• Rahman P, Bartlett S, Siannis F et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am. J. Hum. Genet. 73(3), 677–681 (2003).
   PubMed Web of Science ®Google Scholar